title: One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >or=75 years).
abstract: OBJECTIVE
  The present observational study compares in-hospital and 12-month clinical outcomes in elderly patients with unprotected left main coronary artery disease treated either with coronary artery bypass grafting or drug-eluting stent.
  
  
  METHODS
  From January 2004 to December 2007, 211 patients (pts) with unprotected left main coronary artery (ULMCA) stenosis, aged 75 or older, underwent coronary revascularization either with coronary artery bypass graft (CABG) (106 pts) or drug-eluting stent (DES) (105 pts). The decision to treat with CABG or percutaneous coronary intervention (PCI) was dependent on the patient's and the physician's choice. The occurrence of major adverse cardiac or cerebrovascular events (MACCE: death, nonfatal myocardial infarction, or stroke) and revascularizations was recorded after 1 year of follow-up. A multivariate logistic regression analysis was performed using a propensity score method to take potential baseline differences between groups into account.
  
  
  RESULTS
  In-hospital MACCE rates were 5.7% and 3.8% in the CABG and PCI groups, respectively (P = 0.748). After 1 year of follow-up, these rates were, respectively, 13.9% and 14.9% (P = 0.841), and rates for target vessel revascularization at 12 months were 1.0% and 13.9% (P < 0.001). The PCI group was significantly associated with older age, dyslipidemia, history of cancer, high Euroscore, elevated creatininemia, single-vessel disease, fewer chronic occlusions of the left anterior descending artery, and more LMCA stenosis >or=70%. The multivariate logistic regression analysis was adjusted for age, diabetes, left ventricular ejection fraction, Euroscore, and plasma creatininemia and stratified on the score of propensity to be treated with PCI. In the subgroup below median propensity score, the adjusted odds ratio for 1-year MACCE was OR = 0.91 (95% confidence interval: 0.14 to 5.98; P = 0.924) whereas OR was 0.16 (0.04-0.69; P = 0.013) in the subgroup above median propensity score.
  
  
  CONCLUSIONS
  In patients with a high probability of being treated with PCI (older age, high Euroscore, high creatininemia, single-vessel disease, ...), the 1-year risk of MACCE was significantly lower in PCI- than in CABG-treated subjects. No significant difference was found in other cases.
authors.affiliation: Cardiovascular and Metabolic Pole, Rangueil Hospital, Toulouse, France.
authors.forename: Rabeh
authors.initials: R
authors.lastname: Ghenim
authors.forename: Jérôme
authors.initials: J
authors.lastname: Roncalli
authors.forename: Amir M
authors.initials: AM
authors.lastname: Tidjane
authors.forename: Vanina
authors.initials: V
authors.lastname: Bongard
authors.forename: Abdelkader
authors.initials: A
authors.lastname: Ziani
authors.forename: Nicolas
authors.initials: N
authors.lastname: Boudou
authors.forename: Nicolas
authors.initials: N
authors.lastname: Dumonteil
authors.forename: Bertrand
authors.initials: B
authors.lastname: Marcheix
authors.forename: Bertrand
authors.initials: B
authors.lastname: Léobon
authors.forename: Didier
authors.initials: D
authors.lastname: Carrié
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D016001:Confidence Intervals; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000601:surgery* / Q000628:therapy; D054855:Drug-Eluting Stents; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D013318:Stroke Volume; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016277:Ventricular Function, Left
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin